Case 3: Secondary Amenorrhea & Galactorrhea - Full Explanation

The Clinical Picture

• Secondary amenorrhea (no periods) for 8 months
• Spontaneous bilateral milky breast discharge (galactorrhea)
• NOT pregnant (urine hCG negative)
• NOT on any medications

Lab Interpretation (Value by Value)

1. Free Prolactin: 185 ng/mL (Normal: <25 ng/mL) -- MARKEDLY ELEVATED

• High prolactin acts on the hypothalamus to inhibit GnRH (gonadotropin-releasing hormone) secretion via a short feedback loop
• This is sometimes called "functional hypogonadotropic hypogonadism"
• Without GnRH pulsation, the pituitary cannot release FSH and LH
• Without FSH/LH, the ovary does not produce estrogen or ovulate - hence amenorrhea
• Prolactin directly stimulates breast tissue to produce milk - hence galactorrhea

2. Serum FSH: 2.1 mIU/mL (Normal follicular phase: 3.5-12.5) -- LOW

• FSH is below the lower limit of normal
• This confirms the pituitary is NOT being stimulated to produce gonadotropins
• This rules out primary ovarian failure (which would show HIGH FSH)

3. Serum LH: 1.8 mIU/mL (Normal follicular phase: 2.4-12.6) -- LOW

• LH is also suppressed, confirming central (hypothalamic) suppression
• The pattern of low FSH + low LH = "hypogonadotropic hypogonadism" - the problem is upstream (brain), not the ovary

4. Estradiol (E2): 14 pg/mL (Normal follicular phase: 12.5-166) -- LOW-NORMAL / BORDERLINE LOW

• This is at the very bottom of the reference range
• Without adequate FSH/LH stimulation, the ovaries are not producing estrogen properly
• Low estrogen explains why the patient has no menstrual periods
• Prolonged low estrogen also puts her at risk for osteoporosis if untreated

5. TSH: 2.2 micro IU/mL (Normal: 0.4-4.5) -- NORMAL

• This is critically important for the differential diagnosis
• Primary hypothyroidism causes high TSH, which stimulates excess TRH (thyrotropin-releasing hormone), and TRH also stimulates prolactin release - this can mimic a prolactinoma
• A normal TSH here rules out hypothyroidism as the cause of hyperprolactinemia
• This narrows the diagnosis toward a true prolactinoma

Pattern Recognition: The Diagnostic Logic

Next Steps (What Would Follow in a Real Case)

1. MRI pituitary with gadolinium - to visualize the adenoma
2. Formal visual field testing - macroadenomas can compress the optic chiasm causing bitemporal hemianopia
3. Bone density scan (DEXA) - because of prolonged estrogen deficiency and fracture risk

• First-line: Dopamine agonist (cabergoline or bromocriptine) - these drugs mimic dopamine, suppress prolactin secretion, and often shrink the tumor
• Surgery (transsphenoidal) reserved for drug resistance or intolerance

Key Physiology Recap

Prolactin is normally kept LOW by dopamine from the hypothalamus. A prolactinoma "escapes" this inhibition, secreting prolactin autonomously. The excess prolactin then feeds back to suppress GnRH, collapsing the entire hypothalamic-pituitary-gonadal (HPG) axis. The result: no FSH, no LH, no ovarian estrogen, no ovulation, no periods - and active stimulation of milk production.

Prenatal Testing: Invasive and Non-Invasive Techniques

NON-INVASIVE TECHNIQUES

1. Ultrasonography (Ultrasound)

• What it does: Uses high-frequency sound waves to image the fetus in real time
• Timing:
  • 1st trimester (11-14 weeks): Nuchal translucency (NT) measurement - fluid at the posterior neck is measured; increased fluid is associated with Down syndrome (trisomy 21), other trisomies, and cardiac defects
  • 2nd trimester (18-20 weeks): Detailed "anomaly scan" - detects structural malformations including anencephaly, spina bifida, omphalocele, gastroschisis, cleft lip/palate, cardiac defects
• Also measures: Biparietal diameter (BPD), femur length, abdominal circumference - to assess growth and gestational age
• Limitations: Screening only; does not provide chromosomal/genetic diagnosis

2. Maternal Serum Screening

First Trimester Combined Screening (10-13 weeks)

• PAPP-A (pregnancy-associated plasma protein A)
• Free beta-hCG
• Combined with nuchal translucency (NT) ultrasound
• Detects ~85-90% of Down syndrome cases

Second Trimester "Quad Screen" (15-20 weeks)

• AFP rises in open neural tube defects (spina bifida, anencephaly) because it leaks out of the open defect into amniotic fluid and maternal blood
• AFP falls in Down syndrome and trisomy 18

3. Non-Invasive Prenatal Testing (NIPT) / Cell-Free DNA Screening

• Sample: Maternal blood draw
• Principle: From ~4-6 weeks, placental trophoblasts undergo apoptosis and shed fragments of cell-free fetal DNA (cffDNA) into the maternal circulation. This cffDNA makes up 5-50% of all cfDNA in maternal plasma. It can be isolated and sequenced.
• Method: Massive parallel "shotgun" sequencing - millions of DNA fragments are amplified, sequenced, and mapped to the human genome. An overrepresentation of chromosome 21 fragments indicates trisomy 21, etc.
• Timing: Can be performed from 10 weeks gestation onward
• Accuracy:
  • Trisomy 21: ~99%
  • Trisomy 18: ~96%
  • Trisomy 13: ~91%
• Also detects: Sex chromosome abnormalities, some microdeletions (e.g., 22q11 deletion)
• Important limitation: NIPT is still a screening test - a high-risk result must be confirmed by invasive testing (CVS or amniocentesis) before any clinical decision is made
• Cost-effectiveness: Most cost-effective when used after a high-risk first-trimester combined test result (≥1:150 trisomy risk)

INVASIVE TECHNIQUES

1. Amniocentesis

• What is sampled: Amniotic fluid (contains shed fetal cells and AFP)
• Timing: Typically 15-20 weeks of gestation (not before 15 weeks - too little fluid)
• Technique:
  1. Ultrasound performed first to confirm fetal viability, gestational age, position, placental location
  2. A needle is inserted transabdominally under continuous ultrasound visualization into the amniotic sac
  3. Approximately 20-30 mL of fluid is withdrawn
• Tests done on amniotic fluid:
  • Karyotype - identifies chromosomal aneuploidies (trisomies, monosomies, translocations)
  • Chromosomal Microarray Analysis (CMA) - detects copy number variants (CNVs) at much higher resolution than karyotype; currently the preferred first-line test when fetal anomalies are seen on ultrasound
  • AFAFP (amniotic fluid AFP) - detects open NTDs (when used with ultrasound, detects ~99% of open spina bifida cases)
  • FISH - rapid screening for common aneuploidies (chromosomes 13, 18, 21, X, Y) within 1-2 days; now less used since CMA is faster and more informative
  • DNA sequencing / gene panels / exome sequencing - for specific single-gene disorders
  • Biochemical enzyme assays - for metabolic disorders
• Results turnaround: Karyotype takes 1-2 weeks (cell culture needed); CMA takes 5-7 days
• Complications:
  • Procedure-related fetal loss: ~1 in 300-909 (varies by center experience) - a small increase above the baseline 1-2% pregnancy loss rate at this gestation
  • Rare: amniotic fluid leakage, infection, fetal needle injury
  • Early amniocentesis (<14 weeks) is no longer recommended - carries 3x higher spontaneous abortion risk and 6-7x risk of talipes equinovarus (club foot)

2. Chorionic Villus Sampling (CVS)

• What is sampled: Chorionic villi - placental tissue derived from the extraembryonic part of the early embryo (trophoblasts), which are genetically identical to the fetus
• Timing: 10-14 weeks of gestation (earlier than amniocentesis - this is its major advantage)
• Technique: Two routes, both performed under continuous ultrasound guidance:
  1. Transcervical CVS: A flexible catheter is advanced through the cervix into the placental mass - aspirates 5-40 mg of villus tissue
  2. Transabdominal CVS: A spinal needle is inserted through the abdomen into the placenta
  • The method chosen depends on placental position
• Tests done: Same as amniocentesis - karyotype, CMA, DNA sequencing, biochemical assays. Success rate >99% for chromosomal analysis
• Advantage over amniocentesis: Results available in the first trimester, allowing earlier management decisions and, if elected, earlier termination
• Limitation: Cannot measure AFAFP (no amniotic fluid sampled), so open NTDs must be excluded by maternal serum AFP + ultrasound
• Complications:
  • Procedure-related fetal loss: ~1 in 450 (similar to amniocentesis at experienced centers)
  • Chromosomal mosaicism (~1% of CVS results are ambiguous due to mosaicism - may require follow-up amniocentesis)
  • Historical concern about limb reduction defects (not confirmed in large series when done after 10 weeks by experienced operators)

3. Cordocentesis / Percutaneous Umbilical Blood Sampling (PUBS)

• What is sampled: Fetal blood directly from the umbilical vein
• Timing: From 14 weeks onward, most commonly used from 18-20 weeks onward
• Technique: Ultrasound is used to guide a needle percutaneously into the umbilical cord vein at the placental insertion point
• Uses:
  • Rapid karyotyping (fetal lymphocytes divide quickly - results in days)
  • Diagnosis of hematological conditions (e.g., fetal anemia, hemoglobinopathies, thrombocytopenia)
  • Fetal infection diagnosis (fetal blood culture, serology)
  • Clarifying mosaic results from CVS/amniocentesis
  • Fetal growth restriction assessment
• Complications: Slightly higher fetal loss rate than amniocentesis; reserved for specific indications

Summary Comparison Table